P3 Health Partners Q2 revenue rises 9% to $386 million; raises 2026 EBITDA outlook
P3 Health Partners reported second quarter 2026 total revenue of $386 million, up 9% from a year earlier, and net income of $15.7 million, compared with a net loss of $43.7 million in the prior-year quarter. The company raised its full-year 2026 adjusted EBITDA guidance to $80 million to $110 million, but the quarter includes favorable payer settlements and prior-year development, and at-risk membership fell 10% year over year.
Key points
- Q2 2026 net income was $15.7 million, versus a net loss of $43.7 million in Q2 2025.
- Q2 2026 adjusted EBITDA was $54.4 million, versus a loss of $17.1 million a year earlier.
- Medical margin was $97.8 million for the quarter; excluding payer settlements and prior-year development, it was $52.9 million.
- Full-year 2026 guidance: total revenue $1.5 billion to $1.6 billion; adjusted EBITDA $80 million to $110 million.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.